Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Epilepsia. 2021 Oct 7;62(12):3091–3104. doi: 10.1111/epi.17090

Figure 1. Outline of the experimental design using two different seizure threshold models.

Figure 1

A) Seizure thresholds were determined by timed intravenous pentylenetetrazole (PTZ) infusion. Following determination of basal seizure thresholds, rats (n = 8) received intraperitoneal (i.p.) injections of OV329 (5, 20, and 40 mg/kg) and saline as vehicle control (3 ml/kg) in a crossover design 5½ h before test battery for adverse effects and 6 h before PTZ infusion. For more details, refer to text. B) Seizure thresholds were determined in fully amygdala-kindled rats. Rats were kindled via a chronically implanted electrode in the right amygdala until fully kindled. Determination of seizure thresholds (afterdischarge thresholds, ADT) was performed until reproducible before onset of drug and vehicle trials. Rats (n = 8) received intraperitoneal (i.p.) injections of OV329 (30 and 40 mg/kg) and saline as vehicle control (3 ml/kg) in an alternating design starting with vehicle as indicated in the figure. The post-control for the previous dose served as pre-control for the subsequent dose. Thus, each rat served as its own control. Pretreatment time was 6 h. Adverse effects were assessed 30 min before ADT determination. In addition to the ADT, further seizure parameters (generalized seizure threshold, seizure severity, seizure duration, afterdischarge duration) were determined.